- Home
- GENI vs GLPG Comparison
GENI vs GLPG Comparison
Compare GENI & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENI | GLPG |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United Kingdom | Belgium |
| Employees | N/A | 704 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENI | GLPG |
|---|---|---|
| Price | $5.18 | $31.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | $13.19 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 5.9M | 96.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.73 | N/A |
| Revenue Next Year | $28.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.96 | $22.59 |
| 52 Week High | $13.73 | $37.78 |
Technical Indicators
Market Signals| Indicator | GENI | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 29.30 | 36.85 |
| Support Level | N/A | $30.57 |
| Resistance Level | $6.75 | $33.67 |
| Average True Range (ATR) | 0.43 | 0.79 |
| MACD | 0.03 | -0.19 |
| Stochastic Oscillator | 11.46 | 3.85 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.